EXPAREL Use in Femoral Nerve Block for Total Knee Arthroplasty Further Supported by Additional Data from Phase 3 Pivotal Study, sNDA Submission Planned for Second Quarter 2014

[Business Wire] – Pacira Pharmaceuticals, Inc. today announced additional Phase 3 data supporting the efficacy and safety of EXPAREL® to achieve a femoral nerve block in patients undergoing total knee arthroplasty. more

View todays social media effects on PCRX

View the latest stocks trending across Twitter. Click to view dashboard

See who Pacira is hiring next, click here to view